Methoxy Polyethylene Glycol-Epoetin Beta
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Methoxy Polyethylene Glycol-Epoetin Beta
- Methoxy polyethylene glycol-epoetin beta: From an Erythropoiesis-Stimulating Agent to Primary Release Disorder of Platelets
Methoxy polyethylene glycol-epoetin beta: From an Erythropoiesis-Stimulating Agent to Primary Release Disorder of Platelets
One-Sentence Summary
Methoxy polyethylene glycol-epoetin beta is a long-acting erythropoiesis-stimulating agent (ESA) that acts on the erythropoietin receptor to promote red cell production. The TxGNN model predicts it may be effective for primary release disorder of platelets. There are currently 0 clinical trials and 0 publications supporting this prediction, so it is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence data compiled for this report |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, the drug is a long-acting ESA that acts on the erythropoietin receptor to stimulate red cell production.
The predicted condition is a platelet secretion defect, which arises from intrinsic abnormalities in platelet granules or signalling. Erythropoietin receptor agonism is not known to correct these abnormalities, so no mechanistic link is established. The high TxGNN score is a computational output only.
The other predicted indications show the same pattern:
- Platelet function and coagulation disorders (Glanzmann thrombasthenia, pseudo-von Willebrand disease, heparin cofactor 2 deficiency, antithrombin deficiency type 2, factor 5 excess, thrombophilia): there is no plausible direct mechanism. ESAs carry thrombotic risk, so for the prothrombotic conditions the association more likely signals a safety concern than a benefit.
- Diabetic retinopathy (including severe nonproliferative): erythropoietin has been discussed in the literature with conflicting directions, either neuroprotective or pro-angiogenic. This is background knowledge, not evidence in the data, and the neovascularisation risk would need to be resolved first.
- HER2-positive breast carcinoma: ESAs have raised concerns about tumour progression in some settings, so a therapeutic benefit is not supported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13530P | Mircera Solution for Injection 75mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not available |
| SIN13535P | Mircera Solution for Injection 50mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not available |
| SIN13529P | Mircera Solution for Injection 100mcg/0.3ml (Pre-filled Syringe) | Injection, solution | Not available |
All three licences are valid, held by F. Hoffmann-La Roche AG, and are for the injectable route only.
Safety Considerations
Please refer to the package insert for safety information.
Based on general knowledge of the ESA class, rather than data compiled for this report, thrombotic risk and concern about tumour progression are relevant. They would need careful assessment in any bleeding, thrombotic, retinal or oncology setting. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5), with no clinical trials or literature. There is no plausible mechanism linking erythropoietin receptor agonism to platelet release defects. The known thrombotic risk of ESAs is also a concern in the predicted bleeding and thrombotic conditions.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank)
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are required for safety screening
- Approved indication text for the Singapore licences
- Any preclinical or clinical evidence for the predicted indication, found through a targeted literature and trial search
- A thrombotic and neovascularisation risk assessment before any further consideration, especially for the thrombophilia, retinopathy and breast carcinoma predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.